Clinical trial
A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip
NCT02447276 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip
- Lead sponsor
- Regeneron Pharmaceuticals
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- May 31, 2015
- Completion date
- November 30, 2016
- Enrollment
- 421 (actual)
- Sites
- 72
Conditions
As the registry lists them; a condition with its own page is linked.